Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antimicrobial duration for infections associated with osteosynthesis
2021-003914-38Phase 3Active
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Dec 2021
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ampicillin, amoxicillin + clavulanate, cefazolin, cefepime, ceftazidime and 14 more in fracture-related infection (FRI), osteomyelitis (OM) and bacterial disease (2 arms), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoint: Clinical failure at test of cure. Started Dec 2021; status: active.
02
Drugs
ampicillinamoxicillin + clavulanatecefazolincefepimeceftazidime
03
Conditions
fracture-related infection (FRI)osteomyelitis (OM)bacterial disease
Beyond the preview
Go deeper on 2021-003914-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003914-38.